
News from modernretina.com
Media Bias Ratings
Do you disagree?
Edit bias
Learn more about Media Bias Ratings.
Factuality
Learn more about Factuality Ratings
Reveal Factuality Ratings by upgrading to a Premium account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Ownership
Learn more about Ownership categories
Reveal Ownership Data by upgrading to a Vantage account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Top modernretina.com News

Innovation · South KoreaOcugen licenses OCU400 gene therapy for retinitis pigmentosa to Kwangdong Pharma, including $7.5M upfront, $180M+ in milestones, and 25% royalties. Phase 3 BLA filing targeted for 2026.See the Story
$180M+ Sales Milestone Deal: Ocugen Partners with Korean Pharma Giant for Breakthrough Eye Gene Therapy
